Biosimilars in crohn's disease

Journal of Crohn's and Colitis

Volumn 8, Issue 7, 2014, Pages 710-

  Scheinberg, Morton ^a,b  

^a AACD   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTEGRIN; NATALIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; BIOLOGICAL THERAPY; CLINICAL PRACTICE; CROHN DISEASE; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; GASTROENTEROLOGIST; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; KOREA; LETTER; PATENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; EUROPE;

ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; CROHN DISEASE; DRUG APPROVAL; EUROPE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901507530     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.12.002     Document Type: Letter

References (5)

1. Scheinberg M.A., Kay J. The advent of biosimilar therapies in rheumatology-"O brave new world". Nat Rev Rheumatol 2012, 8(7):430-436. [5].
2. Beck A., Reichert J.M. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013, 5(5):621-623.
3. Mulder D.J., Noble A.J., Justinich C.J., Duffin J.M. A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis Oct 2, 2013.
4. Danese S., Gomollon F., Governing Board and Operational Board of ECCO ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013, 7(7):586-589.
5. Scheinberg M.A., Azevedo V.F. Biosimilars in rheumatology: perspective and concerns. What should the rheumatologist know?. Rheumatology (Oxford) Jul 22, 2013.